Genmab A/S Sponsored ADR $GMAB Stake Reduced by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 1.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,077,471 shares of the company’s stock after selling 21,079 shares during the quarter. Pictet Asset Management Holding SA owned 0.17% of Genmab A/S worth $28,909,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of GMAB. EverSource Wealth Advisors LLC raised its holdings in shares of Genmab A/S by 124.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after purchasing an additional 1,174 shares in the last quarter. Sei Investments Co. grew its position in Genmab A/S by 4.2% in the second quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock worth $1,283,000 after buying an additional 2,496 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Genmab A/S by 636.3% in the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after buying an additional 81,434 shares in the last quarter. Quantinno Capital Management LP increased its holdings in shares of Genmab A/S by 64.9% in the second quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock valued at $3,267,000 after buying an additional 62,226 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in shares of Genmab A/S by 48.1% during the 2nd quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock valued at $643,000 after acquiring an additional 10,113 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GMAB. Wolfe Research initiated coverage on Genmab A/S in a research note on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective for the company. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Genmab A/S in a research report on Tuesday, June 23rd. Weiss Ratings cut Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 8th. Finally, BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.93.

Genmab A/S Trading Up 0.6%

Genmab A/S stock opened at $27.64 on Thursday. Genmab A/S Sponsored ADR has a 52 week low of $20.23 and a 52 week high of $35.43. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. The firm has a market capitalization of $17.23 billion, a price-to-earnings ratio of 20.94, a P/E/G ratio of 1.77 and a beta of 0.84. The company has a 50 day moving average price of $26.15 and a 200 day moving average price of $28.69.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.